Long Term Investment, Biotech & High Yield Dividend Stocks

[califax]

Cell Therapeutics Inc. [CTIC]

...markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin’s lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. The company has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. It has a joint venture with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. The company was founded in 1991 and is headquartered in Seattle, Washington.

*****************************************************************
...added to my LONGTIME-portfolio some "CTIC"

HOMEPAGE: http://www.cticseattle.com/

IHUB-THREAD: http://ih.advfn.com/p.php?pid=squote&symbol=CTIC

STOCKCHARTS: http://stockcharts.com/h-sc/ui?s=ctic&p=D&b=5&g=0&id=0

INVESTORS: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-IRHome

******************************************************************

01/27/09 Pixantrone Pre-NDA Communication from FDA
http://ih.advfn.com/p.php?pid=nmona&cb=1233142863&article=35972975&symbol=N%5ECTIC

..."With the potential for three drug approvals in 2009 we are on track to meet our objective of cash flow break even in the fourth quarter of this year."

01/28/09 Pixantrone Increases Progression-Free Survival by 81%
http://ih.advfn.com/p.php?pid=nmona&cb=1233142863&article=35990098&symbol=N%5ECTIC

..."We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL...